Short answer
Quest Diagnostics (DGX) filed its Q1 2026 10-Q quarterly report on Apr 22, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2.9B (up 9.2% year over year) with net income of $252M.
Q1 2026 key financials · XBRL
- Revenue
- $2.9B
- +9.2% YoY
- Net income
- $252M
- +14.5% YoY
- Operating margin
- 13.8%
- EPS (diluted)
- $2.24
- +15.5% YoY
Source: XBRL data from the Quest Diagnostics (DGX) Q1 2026 10-Q on SEC EDGAR. USD.
Quest Diagnostics Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2,895M, up 9.2% YoY from $2,652M, led by DIS revenue growth of 9.4% to $2,832M
- Operating margin 13.8% vs 13.0% YoY; net income $252M vs $220M
- Best performer DIS: requisition volume up 10.9%; worst DS revenue: $63M vs $63M
- Operating cash flow $278M vs $314M; capital expenditures $114M vs $117M
- 2026 capital expenditure estimate $550M; labor, benefit-cost, reimbursement pressures remain headwinds
Risk Factors
- No risk-factors section provided in the submitted filing text
- Share repurchase authorization increased $1 billion in February 2026
- Executive Rule 10b5-1 plan covering up to 8,147 shares adopted February 26, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Quest Diagnostics quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.